The Use of Glucocorticoid in the Management of Adverse Effects Related to Immunocheckpoint Inhibitors.
10.3779/j.issn.1009-3419.2019.10.02
- Author:
Hanping WANG
1
;
Jiaxin ZHOU
2
;
Xiaoxiao GUO
3
;
Yue LI
4
;
Lian DUAN
5
;
Xiaoyan SI
1
;
Li ZHANG
1
Author Information
1. Department of Respirology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
2. Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
3. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
4. Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
5. Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Glucocorticoid;
Immune checkpoint inhibitor;
Immune suppressors;
Immunotherapy-related adverse effects
- From:
Chinese Journal of Lung Cancer
2019;22(10):615-620
- CountryChina
- Language:Chinese
-
Abstract:
Immunocheckpoint inhibitors (ICIs) activated the patients' tumor immunity to kill the tumor cell, and brought new hope to patients with tumor. However, a series of immunocheckpoint inhibitors related adverse effects (irAEs) may also occur based on immune injury. Glucocorticoids are the basis for the treatment of such irAEs. However, the usage, dosage and course of treatment of glucocorticoid in irAEs are different from those in classic autoimmune diseases. Meanwhile, long-term use of large doses of glucocorticoids may cause serious adverse effects too. In this paper, the mechanism, dosage forms, adverse effects and management of glucocorticoids are described in detail, providing references and suggestions for oncologists to apply glucocorticoids in clinical practice.
